Advances in autosomal dominant polycystic kidney disease-2014 and beyond

Cleveland Clinic Journal of Medicine

Volumn 81, Issue 9, 2014, Pages 545-556

  Braun, William E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASOPRESSIN DERIVATIVE;

ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG DEVELOPMENT; HUMAN; HYPERTENSION; INTRACRANIAL ANEURYSM; METABOLISM; PAIN; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIGNAL TRANSDUCTION; URINARY TRACT INFECTIONS;

DRUG DISCOVERY; HUMANS; HYPERTENSION; INTRACRANIAL ANEURYSM; PAIN; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; URINARY TRACT INFECTIONS; VASOPRESSINS;

EID: 84906959915     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.81gr.14001     Document Type: Article

References (74)

1. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2:40-55.
2. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76:149-168.
3. United States Renal Data System. 2013 atlas of CKD & ESRD. Volume 2 - atlas ESRD:172. www.usrds.org/atlas.aspx. Accessed June 4, 2014.
4. Barua M, Cil O, Paerson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009, 20:1833-1838.
5. Harris PC, Bae KT, Rossetti S, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2006; 17:3013-3019.
6. Vujic M, Heyer CM, Ars E, et al. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol 2010; 21:1097-1102.
7. Harris PC. What is the role of somatic mutation in autosomal dominant polycystic kidney disease? J Am Soc Nephrol 2010; 21:1073-1076.
8. Watnick T, He N, Wang K, et al. Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nat Genet 2000; 25:143-144.
9. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343:824-827.
10. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20:205-212.
11. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287-1301.
12. Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66:1561-1569.
13. Jouret F, Lhommel R, Beguin C, et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:1644-1650.
14. Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:838-844.
15. Hiura T, Yamazaki H, Saeki T, et al. Nephrotic syndrome and IgA nephropathy in polycystic kidney disease. Clin Exp Nephrol 2006; 10:136-139.
16. Hossack KF, Leddy CL, Johnson AM, Schrier RW, Gabow PA. Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 1988; 319:907-912.
17. Rossetti S, Chauveau D, Kubly V, et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 2003; 361:2196-2201.
18. Linn FH, Wijdicks EF, van der Graaf Y, Weerdesteyn-van Vliet FA, Bartelds AI, van Gijn J. Prospective study of sentinel headache in aneurismal subarachnoid haemorrhage. Lancet 1994; 344:590-593.
19. Belz MM, Fick-Brosnahan GM, Hughes RL, et al. Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 63:1824-1830.
20. Irazabal MV, Huston J 3rd, Kubly V, et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:1274-1285.
21. Salman A-S, White PM, Counsell CE, et al. Scottish Audit of Intracranial Vascular Malformations Collaborators. Outcome after conservative management or intervention for unruptured brain arteriovenous malformations. JAMA 2014; 311:1661-1669.
22. Vijay A, Vijay A, Pankaj P. Autosomal dominant polycystic kidney disease: a comprehensive review. Nephrourol Mon 2010; 2:172-192.
23. Grantham JJ, Torres VE, Chapman AB, et al. CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354:2122-2130.
24. Bae KT, Grantham JJ. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010; 6:96-106.
25. van den Dool SW, Wasser NM, de Fijter JW, Hoekstra J, van der Geest RJ. Functional renal volume: quantitative analysis at gadoliniumenhanced MR angiography-feasibility study in healthy potential kidney donors. Radiology 2005; 236:189-195.
26. O'Sullivan DA, Torres VE, Heit JA, Liggett S, King BF. Compression of the inferior vena cava by right renal cysts: an unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystic kidney disease. Clin Nephrol 1998; 49:332-334.
27. Tveit DP, Hypolite I, Bucci J, et al. Risk factors for hospitalizations resulting from pulmonary embolism after renal transplantation in the United States. J Nephrol 2001; 14:361-368.
28. Pei Y. A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 2001; 7:151-156.
29. Qian F, Germino GG. "Mistakes happen": somatic mutation and disease. Am J Hum Genet 1997; 61:1000-1005.
30. Takakura A, Contrino L, Zhou X, et al. Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Hum Mol Genet 2009; 18:2523-2531.
31. Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014; 25:18-32.
32. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33:129-137.
33. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med 2011; 364:1533-1543.
34. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004; 279:40419-40430.
35. Verghese E, Ricardo SD, Weidenfeld R, et al. Renal primary cilia lengthen after acute tubular necrosis. J Am Soc Nephrol 2009; 20:2147-2153.
36. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19:102-108.
37. Torres VE. Cyclic AMP, at the hub of the cystic cycle. Kidney Int 2004; 66:1283-1285.
38. Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006; 17:2220-2227.
39. Grantham JJ. Therapy for polycystic kidney disease? It's water, stupid! J Am Soc Nephrol 2008; 19:1-7.
40. Wang CJ, Creed C, Winklhofer FT, Grantham JJ. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol 2011; 6:192-197.
41. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9:1323-1326.
42. Torres VE, Chapman AB, Devuyst O, et al. TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407-2418.
43. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006; 103:5466-5471.
44. Hartman TR, Liu D, Zilfou JT, et al. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet 2009; 18:161-163.
45. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:820-829.
46. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:830-840. Errata in: N Engl J Med 2010; 363:1190 and N Engl J Med 2010; 363:1977.
47. Walz G, Budde K, Eckardt K-U. mTOR inhibitors and autosomal dominant polycystic kidney disease (correspondence). N Engl J Med 2011; 364:287-288.
48. Braun WE, Schold JD, Stephany BR, Spinko RA, Herfs BR. Low dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized control pilot study. Clin J Am Soc Nephrol 2014; 9:881-888.
49. Karihaloo A, Koraishy F, Huen SC, et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22:1809-1814.
50. Fox R, Nhan TQ, Law GL, Morris DR, Liles WC, Schwartz SM. PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. EMBO J 2007; 26:505-515. Erratum in: EMBO J 2007; 26:2605.
51. Carvalhosa R, Deambrosis I, Carrera P, et al. Cystogenic potential of CD133+ progenitor cells of human polycystic kidneys. J Pathol 2011; 225:129-141.
52. Grantham JJ, Mulamalla S, Grantham CJ, et al. Detected renal cysts are tips of the iceberg in adults with ADPKD. Clin J Am Soc Nephrol 2012; 7:1087-1093.
53. Grantham JJ, Cook LT, Wetzel LH, Cadnapaphornchai MA, Bae KT. Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin J Am Soc Nephrol 2010; 5:889-896.
54. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
55. Chapman AB, Torres VE, Perrone RD, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010; 5:102-109.
56. Klahr S, Breyer JA, Beck GJ, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 1995; 5:2037-2047.
57. Thilly N. Low-protein diet in chronic kidney disease: from questions of effectiveness to those of feasibility. Nephrol Dial Transplant 2013; 28:2203-2205.
58. Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant 2014; 29:247-254.
59. Harris PC, Rossetti S. Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010; 6:197-206.
60. Jacquet A, Pallet N, Kessler M, et al. Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int 2011; 24:582-587.
61. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of longacting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68:206-216.
62. Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2014; 9:889-896.
63. van Dijk MA, Kamper AM, van Veen S, Souverjin JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16:2152-2157.
64. Grantham JJ, Uchich M, Cragoe EL Jr, et al. Chemical modification of cell proliferation and fluid secretion in renal cysts. Kidney Int 1989; 35:1379-1389.
65. Tanner GA. Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 1998; 9:1242-1248.
66. Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs 2010; 19:315-328.
67. Tao Y, Kim J, Yin Y, et al. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int 2007; 72:1358-1366.
68. Terryn S, Ho A, Beauwens R, Devuyst O. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta 2011; 1812:1314-1321.
69. Thiagarajah JR, Verkman AS. CFTR inhibitors for treating diarrheal disease. Clin Pharmacol Ther 2012; 92:287-290.
70. Boehn SN, Spahn S, Neudecker S, et al. Inhibition of Comt with tolcapone slows proression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat. Nephrol Dial Transplant 2013; 28:2045-2058.
71. Rees S, Kittikulsuth W, Roos K, Strait KA, Van Hoek A, Kohan DE. Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J Am Soc Nephrol 2014; 25:232-237.
72. Buchholz B, Schley G, Faria D, et al. Hypoxia-inducible factor-1a causes renal cyst expansion through calcium-activated chloride secretion. J Am Soc Nephrol 2014; 25:465-474.
73. Wallace DP, White C, Savinkova L, et al. Periostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease. Kidney Int 20140; 85:845-854.
74. Leuenroth SJ, Crews CM. Targeting cyst initiation in ADPKD. J Am Soc Nephrol 2009; 20:1-3.